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Abstract
Recent studies have indicated that the glutamatergic system is involved in the motivational aspects during the initiation of drug self-
administration. Ascorbic acid (AA), an antioxidant vitamin, is released from glutamatergic neurons, and it modulates the synaptic action of
dopamine and glutamate. In this study the AA effects on the self-administration of morphine and on the morphine withdrawal syndrome have
been investigated.
Wistar rats were allowed to self-administer morphine (1 mg/infusion) during 10 consecutive days for 2 h/session. The number of lever
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dressings was recorded. An intrapritoneal AA injection (500 mg/kg, i.p.), 30 min before morphine self-administration produced a significant
ecrease in the initiation of morphine self administration during all sessions. After the last test session morphine withdrawal symptom signs
MWS) were recorded after naloxone precipitation. Most of MWS (but not all) were decreased by AA application. In conclusion, AA may
hange the motivational processes underlying the morphine self-administration.
2005 Elsevier Ireland Ltd. All rights reserved.
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. Introduction
Both acute and chronic administration of morphine affects
he turnover of the classical brain monoamine neurotransmit-
ers dopamine (DA) noradernaline and 5-hydroxytryptamine
1,2]. Recent studies have indicated that the glutamatergic
ystem is also involved in the morphine tolerance and absti-
ence [3–6]. Administration of glutaminergic antagonist such
s MK-801 and APV modulate the reinforcing effects of drug
buse in animals. Several studies have documented that MK-
01 inhibits the cocaine self-administration [7] and reverses
ts facilitation after chronic exposure to amphetamine [8].
PV increases the lever pressings for cocaine when admin-
stered into the nucleus accumbens (NAC) in rats [9]. There
s, however, little information about the effects of glutamate
eceptor antagonists on morphine self-administration.
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Ascorbic acid (AA) is an antioxidant vitamin that is re-
leased from glutamatergic neurons as a part of the glutamate
reuptake process, in which the high-affinity glutamate trans-
porter exchanges AA for glutamate [10]. Although neurons
are known to use this vitamin in many different chemical and
enzymatic reactions, only recently some evidence has sug-
gested a role for ascorbate in interneuronal communication.
Experimental evidence suggests that AA plays a key role in
modulating central glutamatergic [11] and dopaminergic [12]
systems as well as behavior [13].
The perfusion of cerebral cortical neurons with high doses
of AA (1–3 mM) rapidly and reversibly attenuates NMDA
antagonist-induced inward currents [14]. Other experiments
have shown that low doses of AA could increase the neuronal
activity and induce widespread neuronal oxidative stress on
the primary cortical neurons [15]. One possible explanation
of the divergent effects of increasing AA concentration on
neuronal activity is that AA may shift from a presynaptic
facilitator of glutamate transmission at relatively low extra-
cellular concentration to a blocker of postsynaptic glutamate928-4680/$ – see front matter © 2005 Elsevier Ireland Ltd. All rights reserved.
oi:10.1016/j.pathophys.2005.03.004
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receptors [16]. It has been reported that high doses of AA
suppress the withdrawal symptoms in the opiate addicts [17]
and prevent the development of tolerance and physical de-
pendence on morphine in the mice [18,19]. Recently, it has
been reported that exogenous AA markedly reduces the lo-
comotor activity and the behavioral withdrawal responses in
morphine-treated guinea pigs [20]. Since both glutamater-
gic and dopaminergic systems are involved in morphine tol-
erance and morphine withdrawal symptoms [21] and these
behaviors are greatly affected by AA [16] it is interest-
ing to evaluate the effects of AA on i.v. self-administration
of morphine as well as on morphine withdrawal signs in
rats.
2. Material and methods
2.1. Animals and housing conditions
Male wistar rats (250–300 g) were used. Before surgery for
the infusion system on the basis of ethic committee permis-
sion of Isfahan University, the animals were group-housed
and they received food and water ad libitum. They were main-
tained under a day–night cycle with lights on between 07:00
and 19:00 h. After surgery the animals were placed in indi-
vidual home cages, and they were allowed to recover from
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(21st day) 30 min before the naloxone injection was
given to precipitate withdrawal symptoms.
(4) Saline (vehicle) group which received only tap wa-
ter for 21 days, at the end of experiment (21st
day) 30 min before naloxone injection they received
saline (0.5 ml, i.p.) as vehicle of AA.
(C) All of the animals at the end of experiment (21st day)
received naloxone (2 mg/kg, s.c.) and withdrawal signs
were recorded for 30 min.
2.3. Drugs
Morphine (HCl) was obtained from TEMAD Ltd.,
Teheran, Iran. Naloxone hydrochloride was purchased from
Sigma Co., St Louis, USA. Ascorbic acid was purchased from
Merck AG, Darmstadt, Germany. Morphine and AA were
dissolved in saline.
2.4. Surgery
Animals were anaesthetized with ketamine (150 mg/kg)
and rampon (0.1 mg/kg) and a cannula was inserted into the
jugular vein. The cannula was guided subcutaneously up to
the skull where it was fixed to acurred metal tube, which was
secured on to the skull with small screws and fixed with dental
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rhe operation for 5 days before study itself was started. Dur-
ng the tests food and water were available ad libitum in the
ome cages. The day–night cycle was reversed for 3 days
efore tests, and the animals were recorded during the dark
hase of the cycle.
.2. Experimental design
A) Male rats (n= 30) were divided into three groups:
(1) Control group, which received saline in the self-
administration sessions.
(2) Morphine group, which received morphine in saline
solution (concentration 5 mg/ml) during the self-
administration sessions.
(3) Ascorbic acid–morphine group (AA + morphine),
which received both AA (500 mg/kg, i.p.) 30 min
before each session and morphine in the self-
administration sessions.
B) To determine the effects of the acute administration of
AA on morphine withdrawal symptom signs 40 mor-
phine treated male rats (250–300 g) were used. They
were divided into four groups:
(1) Control group, which had access to tap water for
drinking during 21 days.
(2) Morphine group, which received morphine (dis-
solved in water) for 21 days.
(3) Ascorbic acid group, which received morphine for
21 days, and then divided to three sub groups
which received AA with three doses (100, 500 or
1000 mg/kg in saline i.p.) at the end of experimentcrylic cement.
.5. Procedure
Details of the procedure have been reported previously
22]. Briefly, testing was done in standard conditioning cage
21 cm× 21 cm× 28 cm) placed in a sound attenuated room.
he test cage was equipped with active and passive levers,
cm above the floor, and a red light located 4 cm above
he active lever. The i.v. cannula of the animals tested was
onnected to the infusion pump. The pressing of the ac-
ive lever, marked by the red light resulted in an i.v. infu-
ion of 0.2 ml fluid (5 mg/ml morphine in saline solution or
aline only) during 10 s. A depression of the active lever dur-
ng this time (10 s) did not affect on the infusion of drug.
he pressing of the passive lever had no programmed conse-
uences.
The drug naı¨ve animals were placed in the test cage and
ere allowed to i.v. self-administer a drug solution for 2 h a
ay (for 10 days). The number of the active and passive lever
ressings is recorded by a oscillograph (Harvard).
.6. Withdrawal syndrome signs
Withdrawal syndrome signs were precipitated with a
.c. naloxone injection (2 mg/kg). Withdrawal signs (body
hakes, jumping, climbing, writhing, teeth chattering, irri-
ability, ejaculation, ptosis and diarrhea) within 30 min after
he injection of naloxone on the last day of experiment were
ecorded.
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2.7. Statistical analysis
The data have been presented as means±S.E.M. The
data obtained during self-administration sessions were ana-
lyzed by using analysis of variance (ANOVA) with repeated
measures (MANOVA). The number of active and passive
lever pressings during every session were calculated. The
differences in the total number of active and passive lever
pressings (summed over ten sessions) between AA and mor-
phine groups were analyzed by using Student’s t-test. This
method of analysis also was used in the analysis of withdrawal
signs.
3. Results
3.1. Initiation of drug self administration
The self-infusion (SI) data during the initiation of mor-
phine self-administration are presented in Fig. 1. Maximum
values were obtained in a week. There was significant differ-
ence (ANOVA, P< 0.05) between numbers of self-infusions
in three groups. Self-infusion of the morphine alone resulted
in an addiction of the rats as shown by the several fold higher
pressing number of the active lever providing the morphine
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Fig. 2. The mean number of self-infusions indicated by the pressings of
active and passive levers in the control, morphine and morphine + ascorbic
acid rat groups during 10 days of self-administration. The passive lever
provided saline as also the active lever (marked by a red lamp) in the control
group while the active lever provided morphine saline solution in the two
other groups. In the morphine group the number pressings of the active
reinforcement lever giving morphine solution in the morphine alone group
was several times higher than that of the passive, i.e., saline providing lever.
There was a significant difference between the morphine alone (P< 0.01) and
the control and morphine-AA groups, but there was no significant difference
between control and morphine-AA groups. The red lamp above the active
lever seemed to increase slightly the use of this lever compared to the passive
lever as shown by the control and morphine-AA group data.
lever pressings in the AA receiving group was significantly
less (t-test, P< 0.01) than in the group receiving morphine
only (Fig. 2). There was no significant difference between
the total active lever pressings of the control and AA groups.
The total number of the passive lever pressings in the AA,
vehicle and morphine groups did not reveal any significant
differences (ANOVA, P> 0.05) (Fig. 3).
3.2. Withdrawal syndrome signs
Table 1 shows the effects of AA (500 mg/kg, i.p.) on the
withdrawal syndrome signs. Controls did not show any of de-
fined withdrawal signs. The i.p. administration of AA during
the 10 days greatly attenuated most of the withdrawal signs
specially ptosis, teeth chattering, wet dog shaking, jumping
and climbing in comparison to these signs in the morphine
group. In comparison with the morphine group, an acute AA
administration 30 min before the naloxone injection greatly
attenuated in morphine addicted rats the withdrawal signs
like ptosis, teeth chattering and wet dog shaking, but it did
not affect jumping, diarrhea, and it even increased ejacula-
tions.
4. Discussionolution. There was no significant difference between con-
rol (saline) and morphine + AA groups, indicating that AA
500 mg/kg, i.p.) resulted in a significant decrease in the num-
er of self-infusions (Figs. 1 and 2). The total number of active
ig. 1. The increase of self-infusions of morphine during the experiment.
lease note that in the beginning morphine + ascorbic acid infusions were
ess than morphine only and that the increase was seen only after a few days,
ut it remained due to ascorbic acid at much lower level than morphine only
see also Fig. 2). bIn the present study AA injection (500 mg/kg, i.p.) 30 min
efore every session caused a decrease in the number of active
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Table 1
Effects of i.p. administration of ascorbic acid (100, 500, 1000 mg/kg), 30 min before naloxone injection on naloxon-precipitated withdrawal syndrom signs in
morphine dependent rats
Withdrawal signs Morphine group only AA and morphine (100 mg/kg) AA and morphine (500 mg/kg) AA and morphine (1000 mg/kg)
Wet-dog shakes 6.6 4.6 2.6* 1.6*
Teeth chattering 6.6 3.6* 1.6* 0.6*
Ptosis 6.6 1.6* 1.6* 0.6*
Jumping 6.6 5.6 6.6 5.6
Climbing 6.6 6.6 5.6 6.6
Diarrhea 6.6 5.6 5.6 4.6
Ejaculation 6.6 3.6* 5.6* 6.6*
Salivation 6.6 2.6* 0.6* 0.6*
Lacrimation 6.6 3.6* 0.6* 0.6*
Numbers denote the number of rats showing positive signs relative to the total number of rats tested.
∗ P< 0.05 compared with the morphine withdrawal group by the Fisher exact test.
lever pressings to obtain morphine in rats. The MWS signs
were depressed in AA receiving rats in comparison with the
morphine addicted animals. These findings are in agreement
with the previous studies, which have shown that AA sup-
presses MWS in opiate addicts [23] and prevents the devel-
opment of tolerance to and physical dependence on morphine
in mice [24] and reduces the locomotor and behavioral with-
drawal responses in morphine treated guinea pigs [20]. More
recently Evangelou and Kalfakakou [23] have shown that a
high orally administered AA dose decreased the withdrawal
syndrome problems in heroin addicts.
We also found that, compared to the morphine group, the
AA administration 30 min before each session significantly
decreased, most of the withdrawal signs after naloxan injec-
tion. These results showing the inhibitory effects of chronic
AA administration on opiate withdrawal signs confirm pre-
vious findings in humans [25] and mice [24].
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On the other hand the injection of AA (500 mg/kg, i.p.)
30 min before thernaloxone injection in morphine addicted
rats (acute effect) had no significant effects on some of mor-
phine withdrawal signs including: jumping, climbing and di-
arrhea, and even it could increase ejaculation, although it
could significantly reduce the head/body shaking and face
washing and rearing (Table 1). These findings suggest that
they are controlled by different mechanisms. It may also re-
flect a poor penetration of AA into the brain that has been
reported following acute systemic AA administration [26].
Apart from these observations rats exhibited no other signifi-
cant changes in the spontaneous behavior following acute or
chronic administration of AA.
The mechanisms involved in the suppression of the toler-
ance development to and physical dependence on morphine
and morphine withdrawal response by chronic AA treatment
is unknown. That could include an inhibition of opioid re-
ceptor binding by AA, effects on second messengers or more
subtle effects on transmitter release and neuronal function
[27]. Although the inhibition of opioid receptor binding by
AA has been observed in guinea pig brain homogenates, this
effect is unlikely to have been involved in the present study,
because AA has no effect on opioid receptor binding in in-
tact tissue preparations [28]. Likewise, although AA has been
shown to suppress the opiate induced compensatory increase
of cAMP in NG 108-15 hybrid tumor cells [29], the signifi-
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rig. 3. The number of responses of the passive lever pressings plotted vs.
he day of testing in the control (received normal saline), morphine (which
eceived only morphine in self-administration sessions) and AA + morphine
roups, which received ascorbic acid before sessions and morphine in self-
dministration sessions. There was no significant difference between three
roups (P> 0.05).ance of this change in cAMP with respect to development of
piate dependence in normal brain has been questioned [30].
An intriguing possibility arises from the reported finding
hat AA and morphine have opposite effects on membrane
a+, K+-ATPase activity. AA has an inhibitory effect on this
ump whereas morphine has a stimulatory effect [31,32].
ncreased Na+, K+-ATPase activity has been suggested to be
t least partly responsible for the two major opiate effects
n the brain viz. membrane hyperpolarization and inhibition
f neurotransmitter release [33]. Chronic AA administration
ay reduce the stimulatory effect of morphine on this pump
ctivity and inhibit the development of dependence and thus
he subsequent withdrawal response. As AA is a powerful
ydrophilic antioxidant high doses may also have a role on the
edox potentials in the brain, although rat is able to synthesize
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its own AA. Some of the membrane proteins may be redox
sensitive.
In conclusion the present study has confirmed that chronic
administration of AA inhibits the development of morphine
dependence, and it inhibits the morphine withdrawal re-
sponses. Rat model seems to be useful in further studies,
which are needed in the further clarification of the molecular
mechanisms.
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